Previous 10 | Next 10 |
2023-04-20 09:45:00 ET After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. Still, scores of beaten-down tech and biotech stocks remain woefully undervalued right now. As a result, there is a s...
2023-04-19 00:43:05 ET Summary Iovance completed its biologics license application (BLA) for its TIL therapy lifileucel before the end of March 2023 setting the stage for possible commercialization after FDA approval. IOVA's cash position of $471.8 million at the moment is suffici...
2023-03-27 15:56:55 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up 11% Monday afternoon after the late-stage biotech company announced on Friday that it had filed a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for its therapy Lifileu...
2023-03-27 08:52:49 ET First Citizens BancShares ( FCNCA ) +39% deal for First Citizens to buy Silicon Valley Bank. First Republic Bank ( FRC ) +24% inks deal for First Citizens to buy Silicon Valley Bank. Baudax ( BXRX ) +26% Announces Posi...
2023-03-24 18:22:48 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) is up 13% in after-hours trading Friday after reporting it has completed its rolling Biologics License Application for lifileucel for melanoma. Lifileucel, a tumor infiltrating lymphocyte therapy...
2023-03-24 17:28:03 ET Gainers: BridgeBio Pharma ( BBIO ) +14% . Iovance Biotherapeutics ( IOVA ) +10% . Iris Energy ( IREN ) +5% . Alphabet ( GOOGL ) +4% . Zions Bancorporation ( ZION ) +3% . Losers: CRISPR T...
SAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Foo...
2023-03-21 07:43:24 ET A top FDA official said Monday that the agency needs to consider accelerated approval, a regulatory avenue commonly used to expedite the market entry of cancer drugs, for gene therapies. Dr. Peter Marks, who heads the FDA's biologics unit, said that the agency...
Iovance Biotherapeutics, Inc. (IOVA) Q4 2022 Earnings Conference Call February 28, 2023 16:30 ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporate Communications Fred Vogt - Interim President and Chief Executive Officer Igor...
Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q4 GAAP EPS of -$0.64 in-line. Iovance had $478.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2022, compared to $602.1 million at December 31, 2021. Research...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, In...
2024-06-28 04:05:00 ET Earlier this year, share prices of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less...
2024-06-20 07:00:08 ET Reni Benjamin from JMP Securities issued a price target of $23.00 for IOVA on 2024-06-20 06:20:00. The adjusted price target was set to $23.00. At the time of the announcement, IOVA was trading at $8. The overall price target consensus is at $23.83...